German Center for Vertigo and Balance Disorders and Institute for Clinical Neurosciences, Ludwig Maximilians Universität, Marchioninistr. 15, 81377, Munich, Germany.
Department of Neurology, Universitätklinik München Ludwig Maximilians Universität, Marchioninistr. 15, 81377, Munich, Germany.
J Neurol. 2020 Dec;267(Suppl 1):231-240. doi: 10.1007/s00415-020-09805-4. Epub 2020 May 22.
Historical descriptions of fear at heights date back to Chinese and Roman antiquity. Current definitions distinguish between three different states of responses to height exposure: a physiological height imbalance that results from an impaired visual control of balance, a more or less distressing visual height intolerance, and acrophobia at the severest end of the spectrum. Epidemiological studies revealed a lifetime prevalence of visual height intolerance including acrophobia in 28% of adults (32% in women; 25% in men) and 34% among prepubertal children aged 8-10 years without gender preponderance. Visual height intolerance first occurring in adulthood usually persists throughout life, whereas an early manifestation in childhood usually shows a benign course with spontaneous relief within years. A high comorbidity was found with psychiatric disorders (e.g. anxiety and depressive syndromes) and other vertigo syndromes (e.g. vestibular migraine, Menière's disease), but not with bilateral vestibulopathy. Neurophysiological analyses of stance, gait, and eye movements revealed an anxious control of postural stability, which entails a co-contraction of anti-gravity muscles that causes a general stiffening of the whole body including the oculomotor apparatus. Visual exploration is preferably reduced to fixation of the horizon. Gait alterations are characterized by a cautious slow walking mode with reduced stride length and increased double support phases. Anxiety is the critical factor in visual height intolerance and acrophobia leading to a motor behavior that resembles an atavistic primitive reflex of feigning death. The magnitude of anxiety and neurophysiological parameters of musculoskeletal stiffening increase with increasing height. They saturate, however, at about 20 m of absolute height above ground for postural symptoms and about 40 m for anxiety (70 m in acrophobic participants). With respect to management, a differentiation should be made between behavioral recommendations for prevention and therapy of the condition. Recommendations for coping strategies target behavioral advices on visual exploration, control of posture and locomotion as well as the role of cognition. Treatment of severely afflicted persons with distressing avoidance behavior mainly relies on behavioral therapy.
对高处恐惧的历史描述可以追溯到中国和罗马古代。目前的定义将对高处暴露的反应分为三种不同的状态:一种是由于视觉平衡控制受损而导致的生理高度失衡,一种是或多或少令人痛苦的视觉高度不耐受,另一种是在频谱的最严重端出现的恐高症。流行病学研究显示,视觉高度不耐受包括恐高症的终生患病率在成年人中为 28%(女性为 32%;男性为 25%),在 8-10 岁的青春期前儿童中为 34%,无性别优势。成年后首次出现的视觉高度不耐受通常会持续一生,而儿童期早期表现出的良性病程通常会在数年内自行缓解。与精神障碍(如焦虑和抑郁综合征)和其他眩晕综合征(如前庭性偏头痛、梅尼埃病)高度共病,但与双侧前庭病不同。姿势、步态和眼球运动的神经生理学分析显示出对姿势稳定性的焦虑控制,这需要对抗重力肌肉的共同收缩,导致整个身体包括眼动装置的整体僵硬。视觉探索最好减少到对地平线的固定。步态改变的特征是谨慎的缓慢行走模式,步幅缩短,双支撑阶段增加。焦虑是视觉高度不耐受和恐高症的关键因素,导致类似于装死的原始反射的运动行为。焦虑的程度和肌肉骨骼僵硬的神经生理学参数随着高度的增加而增加。然而,它们在距地面约 20 米的绝对高度(姿势症状)和约 40 米(焦虑)时饱和(恐高症参与者为 70 米)。在管理方面,应区分预防和治疗该疾病的行为建议。应对策略的建议针对视觉探索、姿势和运动控制以及认知的作用提供行为建议。对有痛苦回避行为的严重受影响者的治疗主要依赖于行为疗法。